Webinars

Cytek 25 Marker PBMC Validation

Ramji Srinivasan 8/21/2024

Cytek 25 Marker PBMC Validation Download

About the Webinar

In this webinar, Ramji Srinivasan, CEO and Cofounder, presents detailed precision and stability data for our 25-marker spectral flow cytometry panel, designed for immune profiling peripheral blood mononuclear cells (PBMCs) from healthy human blood samples.

Read more about our spectral flow cytometry panel here.

About the Speaker

Before Teiko, Ramji was Cofounder, CEO and Chairman of Counsyl, a women’s health genetic screening laboratory. Counsyl screened over 1M prospective parents, mothers-to-be and women at risk of hereditary cancer. In 2018, Counsyl was acquired by Myriad Genetics, Inc for $375M in cash and stock.

Ramji earned a B.S. in computer science and an M.S. in financial mathematics, both from Stanford University. Ramji also attended Stanford’s Graduate School of Business before dropping out to start Counsyl.

A ring of grey and black in the center split into 3 sections with the words Flow, Mass, Spectral going around it clockwise. A dashed line coming out from the ring separates the rest of the space into three sections. Surrounding the ring are six colored circles each with a white icon. The circles directly opposite each other are the same color, but different shades (red opposite pink, blue opposite light blue, green opposite light green). Red shows a pencil, pink shows a grid-like matrix, Blue shows four dials, light blue shows only two; green shows a heavy metal spectrum with distinct lines, light green shows fluorescence spectrum with overlap. The green circle is in the Mass segment, the red overlaps between Mass and Flow, the Blue overlaps between Mass and Spectral. The Mass segment is the only one without any light colored circles.

Flow vs. Spectral vs. Mass Cytometry: What’s the difference?

What’s the difference between flow, spectral, and mass cytometry? We highlight the differences between these three different cytometry platforms used by drug developers to characterize the immune system so you can determine which platform provides you the richest information to advance your research and therapeutic development.

13 markers should be good enough for my flow panel, right?

“I have a 13 marker panel that analyzes T-cells. And my drug just hit the T-cells, why bother looking at any other immune cell types, like B cells, or NK cells? Even if those other cells are affected, I don’t know how to interpret those results.” The reason is: those extra subsets might predict the difference between success and failure for a drug.

Customer Spotlight: Shernan Holtan, MD

Dr. Shernan Holtan discusses her research into a pregnancy hormone that may hold the key to treating life-threatening graft-vs-host diseases and how Teiko helped her overcome the barriers to high-dimensional immune profiling.

About the Webinar

About the Speaker

You Might Also Like

Flow vs. Spectral vs. Mass Cytometry: What’s the difference?

13 markers should be good enough for my flow panel, right?

Customer Spotlight: Shernan Holtan, MD